Development of In-Vitro Assays to Assess the Potency of Botulinum Neurotoxin Type A (STTR [R41/R42])
The summary for the Development of In-Vitro Assays to Assess the Potency of Botulinum Neurotoxin Type A (STTR [R41/R42]) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Development of In-Vitro Assays to Assess the Potency of Botulinum Neurotoxin Type A (STTR [R41/R42]): Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) that propose to develop new non-animal-based assays to assess the potency of botulinum neurotoxin type A (BoNT/A) in a Good Manufacturing Practice (GMP) commercial environment. Successful projects should have as their goal the development of a test(s) and reagents that could be used for commercial release testing of BoNT/A products. Mechanism of Support. This FOA will utilize the STTR (R41/R42) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-179, which encourages applications under the Small Business Innovation Research (SBIR) (R43/R44) grant mechanisms. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.
Federal Grant Title: | Development of In-Vitro Assays to Assess the Potency of Botulinum Neurotoxin Type A (STTR [R41/R42]) |
Federal Agency Name: | National Institutes of Health |
Grant Categories: | Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | PA-09-178 |
Type of Funding: | Grant |
CFDA Numbers: | 93.103 |
CFDA Descriptions: | Food and Drug Administration_Research |
Current Application Deadline: | May 07, 2012 |
Original Application Deadline: | May 07, 2012 |
Posted Date: | Apr 29, 2009 |
Creation Date: | Apr 29, 2009 |
Archive Date: | Jun 07, 2012 |
Total Program Funding: | |
Maximum Federal Grant Award: | |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- Small businesses
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]] - Similar Government Grants
- • Development and Maintenance of the Animal Food Regulatory Program Standards (U19) Clinical...
- • Use of Digital Health Technologies in Clinical Investigations to Support Drug and Biologic...
- • Cooperative Agreement to Support the World Trade Organization's (WTO) Standards and Trade ...
- • Cooperative Agreement for Long Term Data Collection on Antimicrobial Use in Animals (U01) ...
- • Alliance to Support the Activities of the Integrated Food Safety System (IFSS), including ...
- • Support for Small Scientific Conference Grant Program
- • Cooperative Agreement to Support the World Health Organization (WHO) International Program...
- • Clinical Studies of Safety and Effectiveness of Orphan Products
- More Grants from the National Institutes of Health
- • Botanical Dietary Supplements Translational Research Teams (RM1 Clinical Trial Required)
- • Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)
- • Support for Research Excellence First Independent Research (SuRE-First) Award (R16 - Clin...
- • Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...
- • Limited Competition: Research Resource for Natural Product Nuclear Magnetic Resonance Data...